published meta-analysis   sensitivity analysis   studies

imatinib in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsAman, 2021 0.51 [0.27; 0.96] 0.51[0.27; 0.96]Aman, 202110%385NAnot evaluable deathsdetailed resultsAman, 2021 0.51 [0.27; 0.96] 0.51[0.27; 0.96]Aman, 202110%385NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:56 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 580 - roots T: 290